31 May 2011- A recently published study provides recommendations on European Medicines Agency's communication on medicines. The Agency has already begun implementing some of the findings of the study.
Direct and spontaneous patient reporting can speed up the acquisition of knowledge about adverse effects while supporting greater patient participation in the detection and management of these health threats. For these reasons, HAI Europe and our partners advocate for direct patient reporting to be incorporated into pharmacovigilance activities.
HAI Europe's partners:
30 September 2010 - HAI Europe Statement – The monitoring of medicines safety in the Europe Union (EU) took a step forward following last week’s approval by Parliament of the amendments to EU legislation on Pharmacovigilance. Read more.
Policy Briefs & Reports
HAI Europe Briefing Paper - Direct patient reporting of adverse drug reactions:A fifteen-country survey & literature review. Read more.